Production (Stage)
Lixte Biotechnology Holdings, Inc.
LIXT
$1.33
-$0.0502-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 615.50K | 578.70K | 621.60K | 798.40K | 847.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 706.90K | 613.50K | 983.30K | 1.01M | 966.90K |
| Operating Income | -706.90K | -613.50K | -983.30K | -1.01M | -966.90K |
| Income Before Tax | -709.60K | -617.70K | -986.00K | -1.01M | -971.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -709.60K | -617.70K | -986.00K | -1.01M | -971.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -709.60K | -617.70K | -986.00K | -1.01M | -971.30K |
| EBIT | -706.90K | -613.50K | -983.30K | -1.01M | -966.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.29 | -0.27 | -0.44 | -0.45 | -0.43 |
| Normalized Basic EPS | -0.18 | -0.17 | -0.27 | -0.28 | -0.27 |
| EPS Diluted | -0.29 | -0.27 | -0.44 | -0.45 | -0.43 |
| Normalized Diluted EPS | -0.18 | -0.17 | -0.27 | -0.28 | -0.27 |
| Average Basic Shares Outstanding | 2.47M | 2.25M | 2.25M | 2.25M | 2.25M |
| Average Diluted Shares Outstanding | 2.47M | 2.25M | 2.25M | 2.25M | 2.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |